← Back to Search

PARP Inhibitor

AZD7648 for Cancer

Phase 1 & 2
Waitlist Available
Led By Dr Timothy Yap
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new oral drug, AZD7648, in patients with advanced solid tumors. It aims to find a safe and effective dose, both alone and with other cancer treatments. The safety of the drug is closely monitored.

Eligible Conditions
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Patients With Adverse Events or Serious Adverse Events
Number of Patients With Dose Limiting Toxicities (DLTs)
Secondary study objectives
Accumulation Ratio for Area Under Curve (Rac AUC)
Accumulation Ratio for Cmax (Rac Cmax)
Area Under Plasma Concentration-time Curve From Zero to Infinity (AUCinf)
+9 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Core Module: AZD7648 MonotherapyExperimental Treatment1 Intervention
AZD7648 will be administered orally on an empty stomach
Group II: Combination Module 1: AZD7648 + PLDExperimental Treatment2 Interventions
AZD7648 will be administered in combination with Pegylated liposomal doxorubicin (PLD)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PLD
2015
Completed Phase 3
~1420
AZD7648
2019
Completed Phase 2
~30

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,397 Previous Clinical Trials
289,121,627 Total Patients Enrolled
ParexelIndustry Sponsor
311 Previous Clinical Trials
101,521 Total Patients Enrolled
Dr Timothy YapPrincipal InvestigatorMD Anderson Cancer Center, 1400 Holcombe Blvd. Houston, Texas, 77030
~5 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top